Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer

de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested.

Trial Details

NCT ID
NCT04612907
Phase
NA
Sponsor
Umeå University
Status
RECRUITING
Cancer Type
Hormone-Sensitive Prostate Cancer
Interventions
  • Moderate hypo-fractionation
  • Ultra-hypo-fractionation
Locations (sample)
  • Umeå, Sweden|63.82842,20.25972

Key Eligibility Criteria

  • Signed Informed Consent
  • Histological confirmed prostate cancer
  • Indication for early palliative radiation therapy of low burden metastatic prostate cancer. Low burden as defined by modified CHAARTED trial criter…
  • baseline E-PROM

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hormone-Sensitive Prostate Cancer Trials on Trialify →